- Home
- CR vs ROIV Comparison
CR vs ROIV Comparison
Compare CR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | ROIV |
|---|---|---|
| Founded | 1855 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 28.7B |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CR | ROIV |
|---|---|---|
| Price | $209.38 | $41.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $240.90 | $49.91 |
| AVG Volume (30 Days) | 394.9K | ★ 7.2M |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | ★ 23.96 | N/A |
| EPS | ★ 4.43 | N/A |
| Revenue | ★ $2,305,000,000.00 | $8,260,000.00 |
| Revenue This Year | $26.22 | $562.28 |
| Revenue Next Year | $6.03 | $734.15 |
| P/E Ratio | $47.46 | ★ N/A |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $159.58 | $19.96 |
| 52 Week High | $230.50 | $42.50 |
Technical Indicators
Market Signals| Indicator | CR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 66.22 |
| Support Level | $199.85 | $33.11 |
| Resistance Level | $210.63 | $42.50 |
| Average True Range (ATR) | 9.14 | 1.52 |
| MACD | 1.35 | 0.53 |
| Stochastic Oscillator | 92.47 | 94.46 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.